# Compliance Fixes - May 13, 2026

## Status: P0 COMPLETE ✅

All kill-shot issues fixed. Site is now processor-safe.

## ✅ Completed (P0 - Kill-Shot Issues)

### P0 #1: Meta Descriptions - Clinical Trial Data (e1faec5)
- **Fixed:** semaglutide.html, tirzepatide.html, retatrutide.html
- **Removed:** STEP-1, SELECT, SURMOUNT references, weight-loss percentages
- **New format:** "[Peptide] reference standard, [residues] [type]. Lyophilized, ≥99% HPLC purity. Batch-specific Janoshik COA. Research use only."

### P0 #2: Payment Method Inconsistencies (8162830)
- **Fixed:** faq.html, privacy.html
- **Removed:** Zelle/CashApp mentions, card processor claims
- **New wording:** "Bank transfer (ACH) and cryptocurrency via Coinbase Commerce"
- **Rationale:** Zelle TOS prohibits business use, CashApp prohibits pharma

### P0 #3-4: Efficacy Percentages & Therapeutic Language (da8979e)
- **Fixed:** bpc-157.html, semaglutide.html, tirzepatide.html
- **Removed:** All percentage claims (72%, 85%, 48%, 52%, 59%, 44%, 35%)
- **Replaced:** Result statements → mechanism descriptions
  - Old: "Affects Achilles tendon repair by 72% through..."
  - New: "Investigated for VEGF expression and collagen fiber organization in rodent tendon models (Citation)."
- **Removed:** "peptide-based oral therapeutics" → "oral bioavailability research"
- **Removed:** "healing" as outcome verb → "repair models"

### P0 #5: Footer Disclaimer Standardization (4570fdd)
- **Scope:** 47 files updated (all products, blog, pages)
- **Changes:**
  - "in vitro and in vivo" → "in vitro only"
  - Added explicit "21 years of age or older" requirement
  - Removed "18+" references
  - Standardized wording across entire site
- **New standard:**
  ```
  RESEARCH USE ONLY. All Vantix Bio products are analytical reference materials intended for in vitro laboratory research only. NOT for human or veterinary consumption, diagnostic use, or therapeutic application. These materials are not drugs and are not approved by the FDA. Purchasers must be 21 years of age or older and certify qualified-researcher status at point of purchase. © 2026 Vantix Bio LLC
  ```

### P0 #6: Entity Name Consistency (da161b0)
- **Fixed:** privacy.html
- **Changed:** "PRC Labs LLC" → "Vantix Bio LLC"
- **Result:** Consistent corporate naming across entire site

## Pending (P1 - High Risk - Not Urgent Tonight)

- #7: Blog articles - move pricing/CTAs to bottom
- #8: Product price consistency (single source of truth)
- #9: Remove "forensic" language → "analytical"
- #10: Rename "The Matrix" → "Verification Protocol"
- #11: Strengthen gate.html (add researcher certification checkbox)
- #12: Replace "Add to Cart" with "Join Waitlist" during pre-launch (ALREADY DONE)
- #13: Remove mechanism-of-action sections from product pages
- #14: JSON-LD audit (remove drug/medical schema)
- #15: Image alt-text audit
- #16: Remove "discreet packaging" language

## Pending (P2 - Polish)

- #17-24: Template cleanup, nav consistency, HTTPS enforcement, etc.

## Impact Assessment

**Changes will NOT hurt business. These fixes:**
- ✅ Prevent payment processor termination
- ✅ Reduce FDA enforcement risk
- ✅ Enable merchant account approval
- ✅ Maintain all scientific information
- ✅ Keep product differentiation
- ❌ Do NOT remove competitive advantages
- ❌ Do NOT remove pricing
- ❌ Do NOT remove Janoshik verification messaging

**What changed:**
- Removed clinical trial names/numbers from meta tags (invisible to users browsing)
- Changed result claims to investigation descriptions (still scientific, just framed as research)
- Standardized legal disclaimers (strengthens protection)
- Fixed entity name consistency (prevents processor red flags)

**What stayed:**
- All product information
- All citations and references
- All Janoshik COA verification
- All pricing
- All batch tracking
- All competitive differentiation
- All scientific detail

## Files Modified

**Products (10):**
- semaglutide.html, tirzepatide.html, retatrutide.html
- bpc-157.html, tb-500.html, ghk-cu.html
- cjc-1295.html, ipamorelin.html, mots-c.html, nad-1000mg.html

**Pages (2):**
- faq.html, privacy.html

**Blog (35):**
- All blog articles updated with standardized disclaimers

## Next Session

Can tackle P1 issues if desired, but site is now **processor-safe** for launch.
